Meta-Analysis of Duration of Dual Antiplatelet Therapy in Acute Coronary Syndrome Treated With Coronary Stenting

This study was aimed to evaluate if a shorter course of Dual Anti-Platelet Therapy followed by P2Y12 inhibitor monotherapy is as effective as a 12-month course with fewer bleeding events. Five randomized clinical trials were included, with a total of 18,046 participants. Antiplatelet strategies compared were · aspirin and P2Y12 inhibitor for 12 months · aspirin and P2Y12 inhibitor for 1 to 3 months followed by P2Y12 inhibitor alone. In the end of the study it was found that Patients randomized to 1 to 3 months of DAPT followed by P2Y12 inhibitor monotherapy had statistically significant lower rates of major bleeding (1.42% vs 2.53%; OR 0.53; 95% CI 0.42-0.67; p < 0.001; I2 = 0%) and Also significant reduction in all-cause mortality (1.00% vs 1.42%; OR 0.71; 95% CI 0.53-0.95; p = 0.02; I2=0%) with similar major adverse cardiac events (MACE) (2.66% vs 3.11%; OR 0.86; 95% CI 0.71 – 1.03; p = 0.10; I2 = 0 %) compared to 12 months of DAPT. The study concluded, that a shorter course of DAPT for 1 to 3 months followed by P2Y12 inhibitor monotherapy reduces major bleeding and all course mortality without increasing major adverse cardiac events compared with traditional DAPT for 12 months. Disclaimer: Lupin makes no representation or warranty of any kind, expressed or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any scientific information shared by the HCP on the ­­­STAR UPDATE podcast. You should not allow the contents of this to substitute for your own medical judgment, which you should exercise in evaluating the information on this website.